5-Amino-1MQ (5 mg Vial) Dosage Protocol

Plan based on protocol duration using the 5 mg vial format at 5 mg/day.

• 5-Amino-1MQ Vials (5 mg each):
  • 1 week (5 mg/day = 35 mg total) - 7 vials required
  • 2 weeks (5 mg/day = 70 mg total) - 14 vials required
  • 4 weeks (5 mg/day = 140 mg total) - 28 vials required
• Insulin Syringes (U-100, 1 mL):
  • 1 week: 7 syringes once daily; 14 syringes for the twice-daily alternative.
  • 2 weeks: 14 syringes once daily; 28 syringes for the twice-daily alternative.
  • 4 weeks: 28 syringes once daily; 56 syringes for the twice-daily alternative.
• Bacteriostatic Water (10 mL bottles): Use 1.0 mL per vial for reconstitution.
  • 1 week (7 mL total for 7 vials) - 1 bottle required (10 mL each)
  • 2 weeks (14 mL total for 14 vials) - 2 bottles required (10 mL each)
  • 4 weeks (28 mL total for 28 vials) - 3 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
  • 1 week: 14 swabs once daily; 28 swabs for the twice-daily alternative.
  • 2 weeks: 28 swabs once daily; 56 swabs for the twice-daily alternative.
  • 4 weeks: 56 swabs once daily (1 × 100-count box); 112 swabs for the twice-daily alternative (2 × 100-count boxes).

5-Amino-1MQ 5 mg

View Supplier

U-100 syringes (1 mL capacity; check graduations)

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

• Reconstitute: Add 1.0 mL bacteriostatic water → 5 mg/mL concentration.
• Daily amount range: 2.5–5 mg total per day (subcutaneous); the twice-daily alternative is 2.5 mg per administration.
• Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by instructions.

5-Amino-1MQ is a small molecule investigated as an inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide. Research in cultured fat cells and diet-induced obese mice measured changes in cellular metabolites and animal obesity measures.^[16] These findings do not establish a human benefit, a guaranteed SIRT1 response, or superior bioavailability for this subcutaneous 5 mg vial preparation.^[8]

Concise summary of the subcutaneous regimen.

• Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels^[1][2].
• Schedule: Daily subcutaneous injections; each 5 mg vial provides 1–2 days of material.
• Dose Range: 2.5–5 mg total per day; the twice-daily alternative uses 2.5 mg per administration.
• Reconstitution: 1.0 mL per 5 mg vial (5 mg/mL) for accurate measurements.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Amounts and measurements for the 5 mg vial format.

• Start: 2.5 mg once daily to assess tolerance.
• Target: 5 mg once daily or 2.5 mg twice daily (BID).
• Frequency: Once or twice per day (subcutaneous).
• Vial Duration: Single 5 mg vial lasts 1–2 days at 2.5–5 mg per day.
• Timing: Morning administration preferred; BID dosing may be split AM/PM.

5-Amino-1MQ is a small molecule. A generic peptide-storage guide cannot establish its shelf life, solubility, or sterile handling conditions.

The exact material needs documented preparation and stability instructions. A mouse experiment that used a saline formulation cannot validate a bacteriostatic-water preparation or a multiweek refrigerated use-by limit for a different product.^[8]

5-Amino-1MQ 5 mg dosage information begins with the identity of the material. 5-Amino-1MQ, or 5-amino-1-methylquinolinium, is a small molecule investigated as an NNMT inhibitor, not a peptide.^[16]

A 5 mg vial states a total mass. Before interpreting that mass, the product documentation must identify the chemical form and the basis of the label claim. A concentration calculation cannot verify the vial’s contents.

At a final volume of 1 mL, 5 mg gives a calculated concentration of 5 mg/mL. Each U-100 unit is 0.01 mL, equivalent to 0.05 mg or 50 mcg at that concentration. Those are volume conversions, not evidence that a particular human exposure is safe or effective.

NNMT stands for nicotinamide N-methyltransferase. Researchers have investigated this enzyme as a metabolic target, but different kinds of experiments answer different questions.

The 2014 NNMT knockdown study reduced the enzyme’s expression in mice. It was not a trial of a commercial 5-Amino-1MQ vial.^[1] Later small-molecule research examined NNMT inhibitors in cultured fat cells and diet-induced obese mice. Investigators measured changes in cellular metabolites and animal obesity measures, not outcomes in people using this 5 mg format.^[16]

This is why the mechanism and the dosage question must remain separate. Evidence that an NNMT inhibitor changes a laboratory endpoint does not determine a human dose, route, frequency, or treatment duration.

The cited 5-Amino-1MQ studies are primarily preclinical. In obese mice, researchers observed changes in body composition when NNMT inhibition was combined with a change in diet. These findings do not establish human benefit or the safety of this preparation.^[8]

The pharmacokinetic paper measured the compound after intravenous and oral administration in rats. Rat half-life results do not establish the timing of human subcutaneous exposure.^[5]

Those papers cannot provide a reliable rate of headache, jitteriness, local reactions, or long-term adverse effects in people. Calling the compound generally well tolerated in humans would go beyond the evidence they supply.

Diet was part of the experiment, not background noise. The mouse study compared NNMT inhibition plus a lean-diet substitution with the diet change alone. Its result belongs to that model and comparison.^[8]

When comparing a paper with a vial, check the species, compound form, route, and diluent before considering the outcome. A mechanism involving NAD+ does not, by itself, justify adding other compounds to a human regimen.

A syringe’s maximum volume and its graduation size are separate specifications. A 0.5 mL syringe cannot hold a 1 mL withdrawal. The chosen device must accommodate the stated volume without changing the intended amount.

Safe injection guidance requires a new needle and syringe for vial access and disposal of used equipment. These general principles do not establish that a research-use product is suitable for injection.^[17]

This page explains research context and vial arithmetic. It does not establish a clinically validated 5-Amino-1MQ protocol or provide medical advice, diagnosis, or treatment.

• 1
  
  Nature (2014): Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity

  View Source
• 2
  
  PMC (2024): Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions

  View Source
• 5
  
  PubMed (2021): LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study

  View Source
• 8
  Scientific Reports (2021): Combined NNMT inhibition and reduced-calorie diet in obese mice

  View Source
• 16
  Biochemical Pharmacology (2018; online 2017): Selective and membrane-permeable small-molecule NNMT inhibitors in cells and obese mice

  View Source
• 17
  CDC: Safe injection practices and vial-access equipment

  View Source
• 7
  
  Journal of Medicinal Chemistry (ACS): Bisubstrate inhibitors of NNMT with enhanced activity

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.